Dr. John Cush RheumNow
3 years 2 months ago
ANCA-associated vasculitis: beyond therapy with rituximab?
AAV is a group of multi-system autoimmune small vessel vasculitides which includes GPA, MPA and EGPA.
https://t.co/z8RgNYvBiO https://t.co/NI4z4kSAHQ
Dr. John Cush RheumNow
3 years 2 months ago
Methotrexate - an old trusted friend who deserves better
MTX has been used as the anchor drug for the treatment of RA and PsA for many years. It has been co-prescribed with biologics and JAKi in clinical trials and as well as in clinical practice.
https://t.co/rSHsysJQ46 https://t.co/OKfBiMlqyg
Dr. John Cush RheumNow
3 years 2 months ago
Congratulations to Professor Daniel Aletaha - the New EULAR President. Daniel Aletaha is the Professor and Head of the Division of Rheumatology at the Medical University Vienna https://t.co/NgLM4rk7Xd https://t.co/Z9XisPQb2M
Dr. John Cush RheumNow
3 years 2 months ago
Rheumatoid Arthritis, Radiomics and Interstitial Lung Disease
Drs. Antoni Chan and Vincenzo Venerito discuss abstracts OP0127 and POS0855 presented at EULAR 2023 in Milan, Italy.
https://t.co/SuMMrkwfvk https://t.co/hSSPKIW4Os
Dr. John Cush RheumNow
3 years 2 months ago
SLE Trial: Dual BTK JAK Blockade compared Upadacitinib Monotherapy
Dr. Yuz Yusof discusses abstract OP0139 presented at EULAR 2023 in Milan, Italy.
https://t.co/os1tyiDnuT https://t.co/G0owdGek7f
Dr. John Cush RheumNow
3 years 2 months ago
Difficult to treat RA is Actually Difficult to Define
Dr. Janet Pope discusses abstract OP0134 presented at EULAR 2023 in Milan, Italy.
https://t.co/0J9mH9n8jJ https://t.co/JT1hGp2S5w
Dr. John Cush RheumNow
3 years 2 months ago
How to avoid POLYPHARMACY (taking too many medicines). JAMA overview on DE-prescribing. https://t.co/MNmBuuhsFF https://t.co/HQwcsYwj3N
Several studies were reported at EULAR2023 about Takayasu’s arteritis (vasculitis), a very rare large vessel vasculitis that occurs in young individuals.
One of the primary questions about JAK inhibitor safety, ever since its first approval, has been the risk of herpes zoster. While our patients experience outsized morbidity from zoster, it has not been clear if herpes zoster vaccination is effective in them - but data at EULAR 2023 have helped to answer these questions.
Dr. John Cush RheumNow
3 years 2 months ago
CV and Cancer Risk with JAK inhibitors
Dr. Jonathan Kay discusses abstract OP0132 presented at EULAR 2023 in Milan, Italy.
https://t.co/SZLohnNEa1 https://t.co/ZEv0Q2NSBf
Dr. John Cush RheumNow
3 years 2 months ago
Watch: SpA and Interstitial Lung Disease
Dr. Eric Ruderman discusses abstract OP0006 presented at EULAR 2023 in Milan, Italy.
https://t.co/wsR3gv1jSr https://t.co/ULYbJeoFHi
Dr. John Cush RheumNow
3 years 2 months ago
Efficacy and Safety of Baricitinib in Lupus Nephritis
Dr. Yuz Yusof discusses abstract OP0053 presented at EULAR 2023 in Milan, Italy.
https://t.co/ebQ5RwG2po
@Yuz6Yusof https://t.co/mUp7OXVK9K
